Print
Email
Print Edition Stories
Life sciences equipment supplier Thermo Fisher Scientific Inc. is planning to offer about $3.5 billion in senior notes to cover some costs associated with of its May acquisition of Swedish diagnostics firm Phadia AB.
The notes offering is using as its joint book-running managers Barclays Capital Inc., Merrill Lynch, Pierce, Fenner & Smith Inc. and J.P. Morgan Securities LLC.
Waltham-based Thermo Fisher (NYSE: TMO) said in May that its Phadia buyout is expected to generate a total of $35 million of cost and revenue synergies in 2014, with $10 million generated in 2012. Phadia develops, manufactures and markets diagnostic blood test systems in the allergy and autoimmune disease space.
In July, Thermo Fisher announced that it acquired Ohio company TREK Diagnostic Systems from Chelmsford’s Magellan Bioscience Inc.
Comments
If you are commenting using a Facebook account, your profile information may be displayed with your comment depending on your privacy settings. By leaving the 'Post to Facebook' box selected, your comment will be published to your Facebook profile in addition to the space below.
RSS Feeds
